The article states that selective CRP apheresis could be an effective therapy option for COVID-19 patients with respiratory failure and greatly increased CRP levels, and that initial data from the German registry CACOV are encouraging.
The role of CRP not only as a marker of inflammation but also as an acute phase protein that has been shown to activate the complement system and macrophages is mentioned here. Because "in this immune response, the C-reactive protein (CRP) could have an important function."
The results of the CACOV register are cited as evidence, which reports that all patients mostly recovered relatively quickly from their severe COVID-19 disease after treatment with CRP apheresis.
You can find the article here .